spacer
home > ebr > winter 2019 > gates and doors
PUBLICATIONS
European Biopharmaceutical Review

Gates and Doors

Important discoveries have enabled continued progress in biopharmaceutical sciences; the Nobel Prize in Chemistry was awarded jointly to Frances Arnold for the directed evolution of enzymes and to George Smith and Sir Gregory Winter for the phage display of peptides and antibodies. This work will accelerate the pace of biopharmaceutical drug discovery and open up opportunities for new agents. The Nobel Prize in physiology or medicine was awarded to James Allison and Tasuku Honjo for the discovery of cancer therapy by the inhibition of negative immune regulation. The result of their research, immune checkpoint therapy, is recognised as the fourth pillar in the fight against cancer, supplementing surgery, radiation, and chemotherapy. It has fundamentally changed the outcome for certain groups of patients with advanced cancers.

At the same time, much work remains to be done in the quest to mitigate chronic diseases. The war on cancer persists as steady progress is made in precision medicine. The majority of recent drug approvals have received breakthrough therapy designation by the FDA. These focus mainly on targeted therapies, reflecting greater understanding of the underlying mechanisms. Among the major tumour types, biomarkers help specify patient treatment protocols and to distinguish different cancers, beyond more than just tissue types.

Cancer immunotherapy studies number in the thousands. The enthusiasm for this approach relates to the stunning success achieved in just a few years – alone or in combination protocols. After initial tissue-specific experience, the field has quickly evolved toward a tissue-agnostic paradigm, based on genetic biomarkers.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Print this page
Send to a friend
Privacy statement
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>

White Papers

Finding the Right End-to-End Safety Solution for Your Needs

Bioclinica

With upcoming changes, including the implementation of the International Conference on Harmonisation (ICH) E2B(R3) Electronic Transmission of Individual Case Safety Report and Identification of Medicinal Products (IDMP) standards, the current state of safety reporting can be confusing. Your existing safety system may not be flexible enough to accommodate these changing regulations, which are still moving targets regarding the details needed for a comprehensive solution with the right level of processes, company-to-company integrations and finalized regional rules.
More info >>

 
Industry Events

INTERPHEX 2019

2-4 April 2019, Javits Center, New York

At INTERPHEX, find all of the State-of-the-Art Solutions you need to Cost Effectively Develop and Manufacture Product. INTERPHEX is a premier pharmaceutical, biotechnology, and medical device development and manufacturing event and sponsored by Parenteral Drug Association (PDA). Dedicated to Innovation, Technologies and Knowledge, the show focuses on the entire product development life cycle.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement